Previous close | 0.0950 |
Open | 0.0950 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0950 - 0.0950 |
52-week range | 0.0500 - 0.4100 |
Volume | |
Avg. volume | 3,479 |
Market cap | 4.433M |
Beta (5Y monthly) | 0.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8600 |
Earnings date | 15 May 2024 - 19 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™ is labeled for use as a vascular conduit sol
JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel: “I am very pleased to bring you an update on the Company’s FDA Clearance for DuraGraft™ as well as Marizyme’s business priorities for 2024. “After our last business update on May 3, 2023, the Company has been focused on secur
DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries JUPITER, FL, Oct. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the development of products to address unmet clinical needs, today announced that it was granted a de novo from the U.S. Food and Drug Administration (FDA) for its f